4//SEC Filing
Donovan Joanne M. 4
Accession 0001562180-24-003826
CIK 0001710072other
Filed
May 2, 8:00 PM ET
Accepted
May 3, 6:27 PM ET
Size
11.8 KB
Accession
0001562180-24-003826
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2024-05-02$18.91/sh−3,682$69,627→ 19,897 total - Exercise/Conversion
Common Stock
2024-05-01+10,417→ 23,579 total - Exercise/Conversion
Restricted Stock Units
2024-05-01−10,417→ 10,417 totalExercise: $0.00Exp: 2032-05-01→ Common Stock (10,417 underlying)
Footnotes (4)
- [F1]Includes 1,451 shares purchased on May 15, 2023 and 1,751 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
- [F2]Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
- [F3]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.68 to $19.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.
Issuer
Edgewise Therapeutics, Inc.
CIK 0001710072
Entity typeother
Related Parties
1- filerCIK 0001644087
Filing Metadata
- Form type
- 4
- Filed
- May 2, 8:00 PM ET
- Accepted
- May 3, 6:27 PM ET
- Size
- 11.8 KB